Biogen Pharmachem Industries (BOM:531752) Retained Earnings: ₹ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531752 Biogen Pharmachem Industries Ltd BOM:531752
33 GF Score
Price ₹0.27
GF Value ₹0.48
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Biogen Pharmachem Industries Retained Earnings?

Biogen Pharmachem Industries BOM:531752 -3.57% 33 Retained Earnings is ₹ Mil as of Jun. 2026. GuruFocus rates BOM:531752 with a GF Score™ of 33/100 and a GF Value™ of ₹0.48 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biogen Pharmachem Industries's retained earnings for the quarter that ended in Jun. 2026 was ₹ Mil.

Biogen Pharmachem Industries's quarterly retained earnings increased from Dec. 2025 (₹ Mil) to Mar. 2026 (₹-81.73 Mil) but then declined from Mar. 2026 (₹-81.73 Mil) to Jun. 2026 (₹ Mil).

Biogen Pharmachem Industries's annual retained earnings declined from Mar. 2024 (₹-87.40 Mil) to Mar. 2025 (₹-90.33 Mil) but then increased from Mar. 2025 (₹-90.33 Mil) to Mar. 2026 (₹-81.73 Mil).


Biogen Pharmachem Industries  (BOM:531752) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Biogen Pharmachem Industries Retained Earnings Historical Data

* Premium members only.

The historical data trend for Biogen Pharmachem Industries's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Pharmachem Industries Retained Earnings Chart

Biogen Pharmachem Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -111.26 -106.71 -87.40 -90.33 -81.73

Biogen Pharmachem Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -81.73 -
BOM:531752
33GF Score
Biogen Pharmachem Industries Ltd BOM:531752
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Pharmachem Industries Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ₹ Mil mean?
Biogen Pharmachem Industries (BOM:531752) has a Retained Earnings of ₹ Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Biogen Pharmachem Industries and its competitors.
Is Biogen Pharmachem Industries' Retained Earnings too high?
Biogen Pharmachem Industries' current Retained Earnings is ₹ Mil. Overall, Biogen Pharmachem Industries has a GF Score™ of 33/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogen Pharmachem Industries' Retained Earnings compare to MS and GS?
Biogen Pharmachem Industries' Retained Earnings of ₹ Mil can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Capital Markets company?
A good Retained Earnings depends on the Capital Markets industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Biogen Pharmachem Industries and its competitors. Biogen Pharmachem Industries's current Retained Earnings is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen Pharmachem Industries stock overvalued right now?
Based on GuruFocus' analysis, Biogen Pharmachem Industries (BOM:531752) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹0.48, compared to a current price of ₹0.27 — trading 43.8% below its estimated fair value. The current Retained Earnings is ₹ Mil. Biogen Pharmachem Industries' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Biogen Pharmachem Industries (BOM:531752), the current Retained Earnings is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen Pharmachem Industries (BOM:531752) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen Pharmachem Industries stock appears to be undervalued. The current stock price of ₹0.27 is trading 43.8% below its estimated GF Value™ of ₹0.48. GuruFocus considers Biogen Pharmachem Industries to be Significantly Undervalued.

Key valuation signals for BOM:531752:

  • Retained Earnings: ₹ Mil
  • GF Value™: ₹0.48 vs. price of ₹0.27 (43.8% below fair value)
  • GF Score™: 33/100 with 1 warning sign

No single metric tells the full story. See the BOM:531752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Pharmachem Industries Business Description

Address Jawahar Road, Shop No. 8, First Floor, Makers-1 Building, Rajkot, GJ, IND, 360001
Biogen Pharmachem Industries Ltd is engaged in the business of trading in shares and securities in the present and future markets.
33GF Score

Get the complete analysis for BOM:531752

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.27
Price
₹0.48
GF Value